Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Apr;102(4):916–918. doi: 10.1111/j.1476-5381.1991.tb12276.x

Effects of helospectin I on insulin and glucagon secretion in the mouse.

B Ahrén 1
PMCID: PMC1917999  PMID: 1855119

Abstract

1. The helospectins are peptides structurally related to helodermin, vasoactive intestinal polypeptide (VIP), peptide histidine isoleucine (PHI) and secretin, which all potently stimulate glucagon secretion in the mouse. Therefore, the effects of helospectin I (0.1-0.8 nmol kg-1) on insulin and glucagon secretion under basal conditions and after stimulation with glucose (2.8 mmol kg-1) or the cholinoceptor agonist, carbachol (0.16 mumol kg-1), were examined in vivo in the mouse. 2. Helospectin I potently increased plasma levels of glucagon after its intravenous injection in mice. The increase was observed after only 2 min, and was evident also after 6 min. 3. In contrast, plasma insulin levels were not altered by helospectin I after 2 min, but slightly increased after 6 min. Plasma glucose levels were not altered by the peptide. 4. Carbachol-induced glucagon secretion was markedly potentiated by helospectin I. In contrast, glucose- or carbachol-stimulated insulin secretion was not affected by the peptide. 5. In conclusion, helospectin I markedly stimulates glucagon secretion in the mouse whereas the peptide has no direct action on insulin secretion. This pattern of effect of helospectin I is similar to that previously reported for helodermin, VIP, PHI and secretin in the mouse, i.e., for all peptides belonging to this superfamily of peptides.

Full text

PDF
916

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahrén B. Helodermin stimulates glucagon secretion in the mouse. Peptides. 1989 May-Jun;10(3):709–711. doi: 10.1016/0196-9781(89)90165-4. [DOI] [PubMed] [Google Scholar]
  2. Ahrén B., Karlsson S., Lindskog S. Cholinergic regulation of the endocrine pancreas. Prog Brain Res. 1990;84:209–218. doi: 10.1016/s0079-6123(08)60905-x. [DOI] [PubMed] [Google Scholar]
  3. Ahrén B., Lundquist I. Effects of peptide HI on basal and stimulated insulin and glucagon secretion in the mouse. Neuropeptides. 1988 May-Jun;11(4):159–162. doi: 10.1016/0143-4179(88)90069-8. [DOI] [PubMed] [Google Scholar]
  4. Ahrén B., Lundquist I. Effects of selective and non-selective beta-adrenergic agents on insulin secretion in vivo. Eur J Pharmacol. 1981 Apr 24;71(1):93–104. doi: 10.1016/0014-2999(81)90390-3. [DOI] [PubMed] [Google Scholar]
  5. Ahrén B., Lundquist I. Glucagon immunoreactivity in plasma from normal and dystrophic mice. Diabetologia. 1982 Apr;22(4):258–263. doi: 10.1007/BF00281302. [DOI] [PubMed] [Google Scholar]
  6. Ahrén B., Lundquist I. Interaction of vasoactive intestinal peptide (VIP) with cholinergic stimulation of glucagon secretion. Experientia. 1982 Mar 15;38(3):405–406. doi: 10.1007/BF01949419. [DOI] [PubMed] [Google Scholar]
  7. Ahrén B., Lundquist I. Secretin potentiates cholinergically induced glucagon secretion in the mouse. Acta Physiol Scand. 1986 Dec;128(4):575–578. doi: 10.1111/j.1748-1716.1986.tb08014.x. [DOI] [PubMed] [Google Scholar]
  8. Bjartell A., Persson P., Absood A., Sundler F., Håkanson R. Helodermin-like peptides in noradrenaline cells of adrenal medulla. Regul Pept. 1989 Aug;26(1):27–34. doi: 10.1016/0167-0115(89)90101-8. [DOI] [PubMed] [Google Scholar]
  9. Grundemar L., Högestätt E. D. Vascular effects of helodermin, helospectin I and helospectin II: a comparison with vasoactive intestinal peptide (VIP). Br J Pharmacol. 1990 Mar;99(3):526–528. doi: 10.1111/j.1476-5381.1990.tb12962.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Grunditz T., Persson P., Håkanson R., Absood A., Böttcher G., Rerup C., Sundler F. Helodermin-like peptides in thyroid C cells: stimulation of thyroid hormone secretion and suppression of calcium incorporation into bone. Proc Natl Acad Sci U S A. 1989 Feb;86(4):1357–1361. doi: 10.1073/pnas.86.4.1357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Herbert V., Lau K. S., Gottlieb C. W., Bleicher S. J. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab. 1965 Oct;25(10):1375–1384. doi: 10.1210/jcem-25-10-1375. [DOI] [PubMed] [Google Scholar]
  12. Parker D. S., Raufman J. P., O'Donohue T. L., Bledsoe M., Yoshida H., Pisano J. J. Amino acid sequences of helospectins, new members of the glucagon superfamily, found in Gila monster venom. J Biol Chem. 1984 Oct 10;259(19):11751–11755. [PubMed] [Google Scholar]
  13. Robberecht P., De Neef P., Vandermeers A., Vandermeers-Piret M. C., Svoboda M., Meuris S., De Graef J., Woussen-Colle M. C., Yanaihara C., Yanaihara N. Presence of helodermin-like peptides of the VIP-secretin family in mammalian salivary glands and saliva. FEBS Lett. 1985 Oct 7;190(1):142–146. doi: 10.1016/0014-5793(85)80445-2. [DOI] [PubMed] [Google Scholar]
  14. Vandermeers A., Vandermeers-Piret M. C., Robberecht P., Waelbroeck M., Dehaye J. P., Winand J., Christophe J. Purification of a novel pancreatic secretory factor (PSF) and a novel peptide with VIP- and secretin-like properties (helodermin) from Gila monster venom. FEBS Lett. 1984 Jan 30;166(2):273–276. doi: 10.1016/0014-5793(84)80094-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES